Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
Download your copy of the new events calendar and see all the online workshops, conferences, RAC exams and European online workshops RAPS has planned for 2021 at a glance.
Registration is now open for RAPS Euro Convergence 2021! Attend to join peers from EU and around the world to gain insights and exchange ideas on the regions most pressing issues.
An invaluable resource for any professional engaged in designing, composing, compiling, or commenting on regulatory documentation
From self-assessments to help you identify your strengths and areas to focus on to reference books and online courses that will help you fill in the gaps in your regulatory knowledge, RAPS has the resources to help you prepare for the RAC exam.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
Posted 29 February 2016 | By Michael Mezher
The US Food and Drug Administration (FDA) will award $2 million in grants to fund natural history studies for rare diseases.
Natural history studies are studies that follow the progression of a disease from before it begins through its outcome, which may include a resolution of symptoms, lifelong chronic condition or a patient's death.
For example, natural history studies have identified the six-minute walk distance as an endpoint in clinical trials for potential treatments for Duchenne muscular dystrophy.
For natural history studies, FDA is offering two different grant levels depending on the type of study proposed. For prospective studies involving clinical examinations of patients, the agency will award up to $400,000 per year, for up to five years. For retrospective studies or survey studies FDA is offering up to $150,000 per year for up to two years.
FDA says it will accept applications until 14 October 2016 and will rely on a panel of rare disease and natural history experts to review the proposals. The agency plans to begin funding the winning grants in March 2017.
"Information about a disease's natural history can aid in clinical trial design, identify study end points and lead to faster, better trials – hopefully leading to new and effective diagnostics and treatments," said Gayatri Rao, director of FDA's Office of Orphan Drug Products.
For many rare diseases, FDA says that natural history studies can help identify clinical endpoints and biomarkers that could be used to measure a treatment's effectiveness.
In August, FDA also released a new draft guidance, Rare Diseases: Common Issues in Drug Development, encouraging drugmakers to conduct natural history studies to inform clinical development programs. However, industry groups have called on FDA to clarify its guidance and give examples of how natural history studies can be used to support a product's approval.
The announcement of the grant program coincides with Rare Disease Day, which began in 2008 to raise awareness about rare diseases. According to FDA there are more than 7,000 rare diseases that affect nearly 10% of Americans.
FDA, FDA Voice
Regulatory Focus newsletters
All the biggest regulatory news and happenings.